167 related articles for article (PubMed ID: 33789022)
1. Oral Azacitidine Maintenance for Acute Myeloid Leukemia.
Perissinotti AJ; Benitez LL; Marini BL
N Engl J Med; 2021 Apr; 384(13):e51. PubMed ID: 33789022
[No Abstract] [Full Text] [Related]
2. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.
Roboz GJ; Montesinos P; Selleslag D; Wei A; Jang JH; Falantes J; Voso MT; Sayar H; Porkka K; Marlton P; Almeida A; Mohan S; Ravandi F; Garcia-Manero G; Skikne B; Kantarjian H
Future Oncol; 2016 Feb; 12(3):293-302. PubMed ID: 26785287
[TBL] [Abstract][Full Text] [Related]
3. Oral Azacitidine Maintenance for Acute Myeloid Leukemia. Reply.
Wei AH; Döhner H; Roboz GJ
N Engl J Med; 2021 Apr; 384(13):e51. PubMed ID: 33789023
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia.
Bewersdorf JP; Patel KK; Huntington SF; Zeidan AM
Blood Adv; 2021 Nov; 5(22):4686-4690. PubMed ID: 34525174
[No Abstract] [Full Text] [Related]
5. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Ravandi F; Roboz GJ; Wei AH; Döhner H; Pocock C; Selleslag D; Montesinos P; Sayar H; Musso M; Figuera-Alvarez A; Safah H; Tse W; Sohn SK; Hiwase D; Chevassut T; Pierdomenico F; La Torre I; Skikne B; Bailey R; Zhong J; Beach CL; Dombret H
J Hematol Oncol; 2021 Aug; 14(1):133. PubMed ID: 34454540
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia.
Zhu J; Wu Q; Wang J; Niu T
Expert Rev Hematol; 2022 Apr; 15(4):375-382. PubMed ID: 35437111
[TBL] [Abstract][Full Text] [Related]
7. Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia.
Tamura A; Ishida T; Saito A; Yamamoto N; Yokoi T; Uemura S; Nino N; Fujiwara T; Tahara T; Nakamura S; Kozaki A; Kishimoto K; Hasegawa D; Kosaka Y
Pediatr Blood Cancer; 2018 Oct; 65(10):e27284. PubMed ID: 29893458
[TBL] [Abstract][Full Text] [Related]
8. Response and survival in acute myeloid leukemia patients not candidates to transplantation treated with azacitidine versus palliative treatment: a retrospective study.
Sarmiento Maldonado M; Ocqueteau Tachini M; Pilcante J; Ramírez Villanueva P
Medwave; 2015 Aug; 15(7):e6207. PubMed ID: 26335141
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.
Oshikawa G; Kakihana K; Saito M; Aoki J; Najima Y; Kobayashi T; Doki N; Sakamaki H; Ohashi K
Br J Haematol; 2015 Jun; 169(5):756-9. PubMed ID: 25522128
[No Abstract] [Full Text] [Related]
10. Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Witlox W; Grimm S; Howick J; Armstrong N; Ahmadu C; McDermott K; Otten T; Noake C; Wolff R; Joore M
Pharmacoeconomics; 2023 Aug; 41(8):857-867. PubMed ID: 37129774
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of secondary acute myeloid leukemia with azacitidine : Maintenance of quality of life and independence in advanced age].
Reese J; Velazquez GF; Weckenbrock J; Kolb G
Z Gerontol Geriatr; 2020 Jul; 53(4):362-364. PubMed ID: 32355997
[No Abstract] [Full Text] [Related]
12. Azacitidine in adult patients with acute myeloid leukemia.
Schuh AC; Döhner H; Pleyer L; Seymour JF; Fenaux P; Dombret H
Crit Rev Oncol Hematol; 2017 Aug; 116():159-177. PubMed ID: 28693797
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.
Hunault-Berger M; Maillard N; Himberlin C; Recher C; Schmidt-Tanguy A; Choufi B; Bonmati C; Carré M; Couturier MA; Daguindau E; Marolleau JP; Orsini-Piocelle F; Delaunay J; Tavernier E; Lissandre S; Ojeda-Uribe M; Sanhes L; Sutton L; Banos A; Fornecker LM; Bernard M; Bouscary D; Saad A; Puyade M; Rouillé V; Luquet I; Béné MC; Hamel JF; Dreyfus F; Ifrah N; Pigneux A
Blood Cancer J; 2017 Jun; 7(6):e568. PubMed ID: 28574488
[No Abstract] [Full Text] [Related]
14. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH; Döhner H; Pocock C; Montesinos P; Afanasyev B; Dombret H; Ravandi F; Sayar H; Jang JH; Porkka K; Selleslag D; Sandhu I; Turgut M; Giai V; Ofran Y; Kizil Çakar M; Botelho de Sousa A; Rybka J; Frairia C; Borin L; Beltrami G; Čermák J; Ossenkoppele GJ; La Torre I; Skikne B; Kumar K; Dong Q; Beach CL; Roboz GJ;
N Engl J Med; 2020 Dec; 383(26):2526-2537. PubMed ID: 33369355
[TBL] [Abstract][Full Text] [Related]
15. Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia.
Huschart E; Miller H; Salzberg D; Campbell C; Beebe K; Schwalbach C; Magee K; Adams RH; Ngwube A
Pediatr Hematol Oncol; 2021 Mar; 38(2):154-160. PubMed ID: 33150833
[TBL] [Abstract][Full Text] [Related]
16. A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy.
Kara A; Akın Belli A; Karakuş V; Dere Y; Kurtoğlu E
Turk J Haematol; 2017 Jun; 34(2):192-193. PubMed ID: 28183685
[No Abstract] [Full Text] [Related]
17. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
Wei A; Tan P; Perruzza S; Govindaraj C; Fleming S; McManus J; Avery S; Patil S; Stevenson W; Plebanski M; Spencer A
Br J Haematol; 2015 Apr; 169(2):199-210. PubMed ID: 25643589
[TBL] [Abstract][Full Text] [Related]
18. Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia.
Yamamoto R; Yokoyama A; Yoneda M; Ohashi K; Hosoda T; Kagoo T; Boku S; Ueno H; Yano T
Ann Hematol; 2014 Dec; 93(12):2081-2. PubMed ID: 24863693
[No Abstract] [Full Text] [Related]
19. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
Feld J; Tremblay D; Navada SC; Silverman LR
Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
[TBL] [Abstract][Full Text] [Related]
20. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
Falantes JF; Calderón C; Márquez-Malaver FJ; Aguilar-Guisado M; Martín-Peña A; Martino ML; Montero I; González J; Parody R; Pérez-Simón JA; Espigado I
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):80-6. PubMed ID: 24220615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
